# EDGAR Filing Document

**Accession Number:** 0001944552
**File Stem:** 0001213900-26-057060
**Filing Date:** 2026-5
**Character Count:** 21051
**Document Hash:** c440fea6d77cafc9fed89c6f64ae937b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-057060.hdr.sgml**: 20260514

**ACCESSION NUMBER**: 0001213900-26-057060

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260514

**DATE AS OF CHANGE**: 20260514

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Adlai Nortye Ltd.
- **CENTRAL INDEX KEY:** 0001944552
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-94181
- **FILM NUMBER:** 26981727

**BUSINESS ADDRESS:**
- **STREET 1:** 685 U.S. HIGHWAY ONE, 2ND FLOOR
- **CITY:** NORTH BRUNSWICK
- **STATE:** NJ
- **ZIP:** 08902
- **BUSINESS PHONE:** 848-230-7430

**MAIL ADDRESS:**
- **STREET 1:** 685 U.S. HIGHWAY ONE, 2ND FLOOR
- **CITY:** NORTH BRUNSWICK
- **STATE:** NJ
- **ZIP:** 08902
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Hangzhou Jingyin Investment Partnership (Limited Partnership)
- **CENTRAL INDEX KEY:** 0002014001

**ORGANIZATION NAME:**
- **EIN:** 000000000

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A

**BUSINESS ADDRESS:**
- **STREET 1:** FEICUI HAIAN 2-2-401, WANGJIANG STREET
- **STREET 2:** SHANGCHENG DISTRICT
- **CITY:** HANGZHOU
- **STATE:** F4
- **ZIP:** 310016
- **BUSINESS PHONE:** 86-137-7743-8022

**MAIL ADDRESS:**
- **STREET 1:** FEICUI HAIAN 2-2-401, WANGJIANG STREET
- **STREET 2:** SHANGCHENG DISTRICT
- **CITY:** HANGZHOU
- **STATE:** F4
- **ZIP:** 310016

## Exhibit 99.1

**Exhibit 99.1**

**AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G**

The undersigned being duly authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13G to evidence the agreement of the below-named parties in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, as amended, to file this Schedule 13G (including amendments thereto) jointly on behalf of each such party.

Dated: April 14, 2026

---

| | | | |
|:---|:---|:---|:---|
| **JIN YIN (BVI) LIMITED** | By: | /s/ Shijun Feng | /s/ Shijun Feng |
|  | Name: | Shijun Feng | Shijun Feng |
|  | Title: | Director | Director |
| **Shanghai Gaopei Duwei Biotechnology Co., Ltd.** | By: | /s/ Shijun Feng | /s/ Shijun Feng |
|  | Name: | Shijun Feng | Shijun Feng |
|  | Title: | Director | Director |
| **Hangzhou Jingyin Investment Partnership (Limited Partnership)** | By: | Hangzhou Jingfeng Investment<br> Management Company | Hangzhou Jingfeng Investment<br> Management Company |
|  |  | General Partner | General Partner |
|  |  | By: | /s/ Yueai Jiang |
|  |  | Name: | Yueai Jiang |
|  |  | Title: | Authorized Person |
| **Hangzhou Jingfeng Investment Management Company** | By: | /s/ Shijun Feng | /s/ Shijun Feng |
|  | Name: | Shijun Feng | Shijun Feng |
|  | Title: | Director | Director |
| **Shijun Feng** | By: | /s/ Shijun Feng | /s/ Shijun Feng |
|  | Name: | Shijun Feng | Shijun Feng |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**Issuer:** Adlai Nortye Ltd.

**Title of Class of Securities:** Ordinary shares, par value US$0.0001 per share

**CUSIP Number:** —

**Date of Event Which Requires Filing of this Statement:** 12/31/2023

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [ ] Rule 13d-1(c)

- [x] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>JIN YIN (BVI) LIMITED | Names of Reporting Persons<br>JIN YIN (BVI) LIMITED |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>D8 | Citizenship or Place of Organization<br>D8 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>4561077.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>4561077.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>4561077.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>4561077.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>2.9% | Percent of Class Represented by Amount in Row (9)<br>2.9% |
| 12. | Type of Reporting Person (See Instructions)<br>CO | Type of Reporting Person (See Instructions)<br>CO |

**Comment for Type of Reporting Person:** (1) Representing 4,561,077 Class A ordinary shares of the Issuer held by JIN YIN (BVI) LIMITED.

(2) This percentage is calculated based on a total of (i) 142,241,572 Class A ordinary shares and 16,990,000 Class B ordinary shares outstanding of the Issuer as of April 10th, 2026 as reported in the Issuer's annual report on Form 20-F filed on the same date.

---

| 1. | Names of Reporting Persons<br>Shanghai Gaopei Duwei Biotechnology Co., Ltd. | Names of Reporting Persons<br>Shanghai Gaopei Duwei Biotechnology Co., Ltd. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>F4 | Citizenship or Place of Organization<br>F4 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>4561077.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>4561077.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>4561077.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>4561077.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>2.9% | Percent of Class Represented by Amount in Row (9)<br>2.9% |
| 12. | Type of Reporting Person (See Instructions)<br>CO | Type of Reporting Person (See Instructions)<br>CO |

**Comment for Type of Reporting Person:** (3) Representing 4,561,077 Class A ordinary shares of the Issuer held by JIN YIN (BVI) LIMITED. Shanghai Gaopei Duwei Biotechnology Co., Ltd. holds 100.0% equity interest of JIN YIN (BVI) LIMITED.

---

| 1. | Names of Reporting Persons<br>Hangzhou Jingyin Investment Partnership (Limited Partnership) | Names of Reporting Persons<br>Hangzhou Jingyin Investment Partnership (Limited Partnership) |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>F4 | Citizenship or Place of Organization<br>F4 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>4561077.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>4561077.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>4561077.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>4561077.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>2.9% | Percent of Class Represented by Amount in Row (9)<br>2.9% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

**Comment for Type of Reporting Person:** (4) Representing 4,561,077 Class A ordinary shares of the Issuer held by JIN YIN (BVI) LIMITED. Shanghai Gaopei Duwei Biotechnology Co., Ltd. holds 100.0% equity interest of JIN YIN (BVI) LIMITED. Hangzhou Jingyin Investment Partnership (Limited Partnership) holds 99.0% equity interest of Shanghai Gaopei Duwei Biotechnology Co., Ltd.

---

| 1. | Names of Reporting Persons<br>Hangzhou Jingfeng Investment Management Company | Names of Reporting Persons<br>Hangzhou Jingfeng Investment Management Company |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>F4 | Citizenship or Place of Organization<br>F4 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>4561077.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>4561077.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>4561077.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>4561077.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>2.9% | Percent of Class Represented by Amount in Row (9)<br>2.9% |
| 12. | Type of Reporting Person (See Instructions)<br>CO | Type of Reporting Person (See Instructions)<br>CO |

**Comment for Type of Reporting Person:** (5) Representing 4,561,077 Class A ordinary shares of the Issuer held by JIN YIN (BVI) LIMITED. Shanghai Gaopei Duwei Biotechnology Co., Ltd. holds 100.0% equity interest of JIN YIN (BVI) LIMITED. Shanghai Gaopei Duwei Biotechnology Co., Ltd. holds 100.0% equity interest of JIN YIN (BVI) LIMITED. Hangzhou Jingyin Investment Partnership (Limited Partnership) holds 99.0% equity interest of Shanghai Gaopei Duwei Biotechnology Co., Ltd. Hangzhou Jingfeng Investment Management Company is the general partner of Hangzhou Jingyin Investment Partnership (Limited Partnership), and may be deemed to beneficially own the ordinary shares beneficially owned by Hangzhou Jingyin Investment Partnership (Limited Partnership).

---

| 1. | Names of Reporting Persons<br>Shijun Feng | Names of Reporting Persons<br>Shijun Feng |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>F4 | Citizenship or Place of Organization<br>F4 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>4561077.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>4561077.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>4561077.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>4561077.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>2.9% | Percent of Class Represented by Amount in Row (9)<br>2.9% |
| 12. | Type of Reporting Person (See Instructions)<br>IN | Type of Reporting Person (See Instructions)<br>IN |

**Comment for Type of Reporting Person:** (6) Representing 4,561,077 Class A ordinary shares of the Issuer held by JIN YIN (BVI) LIMITED. Shanghai Gaopei Duwei Biotechnology Co., Ltd. holds 100.0% equity interest of JIN YIN (BVI) LIMITED. Shanghai Gaopei Duwei Biotechnology Co., Ltd. holds 100.0% equity interest of JIN YIN (BVI) LIMITED. Hangzhou Jingyin Investment Partnership (Limited Partnership) holds 99.0% equity interest of Shanghai Gaopei Duwei Biotechnology Co., Ltd. Hangzhou Jingfeng Investment Management Company is the general partner of Hangzhou Jingyin Investment Partnership (Limited Partnership), and may be deemed to beneficially own the ordinary shares beneficially owned by Hangzhou Jingyin Investment Partnership (Limited Partnership). Shijun Feng holds 100.0% equity interest of Hangzhou Jingfeng Investment Management Company.

---

**Item 1(a). Name of Issuer:**
Adlai Nortye Ltd.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
c/o PO Box 309, Ugland House, Grand Cayman KY1-1104, Cayman Islands

**Item 2(a). Name of Person Filing:**
(i) JIN YIN (BVI) LIMITED

(ii) Shanghai Gaopei Duwei Biotechnology Co., Ltd.

(iii) Hangzhou Jingyin Investment Partnership (Limited Partnership)

(iv) Hangzhou Jingfeng Investment Management Company

(v) Shijun Feng

**Item 2(b). Address of Principal Business Office:**
JIN YIN (BVI) LIMITED
Craigmuir Chambers, Road Town, Tortola, VG 1110, British Virgin Islands

Shanghai Gaopei Duwei Biotechnology Co., Ltd.
Rm 401, Block 2, Building 2, Feicui Hai'an, Wangjiang Street, Shangcheng District, Hangzhou, Zhejiang Province, the People's Republic of China

Hangzhou Jingyin Investment Partnership (Limited Partnership)
Rm 401, Block 2, Building 2, Feicui Hai'an, Wangjiang Street, Shangcheng District, Hangzhou, Zhejiang Province, the People's Republic of China

Hangzhou Jingfeng Investment Management Company
Rm 401, Block 2, Building 2, Feicui Hai'an, Wangjiang Street, Shangcheng District, Hangzhou, Zhejiang Province, the People's Republic of China

Shijun Feng
Rm 401, Block 2, Building 2, Feicui Hai'an, Wangjiang Street, Shangcheng District, Hangzhou, Zhejiang Province, the People's Republic of China

**Item 2(c). Citizenship:**
JIN YIN (BVI) LIMITED
British Virgin Islands

Shanghai Gaopei Duwei Biotechnology Co., Ltd.
The People's Republic of China

Hangzhou Jingyin Investment Partnership (Limited Partnership)
The People's Republic of China

Hangzhou Jingfeng Investment Management Company
The People's Republic of China

Shijun Feng
The People's Republic of China

**Item 2(d). Title of Class of Securities:**
Ordinary shares, par value US$0.0001 per share

**Item 2(e). CUSIP Number:**
—

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

See Item 9 of each cover page.

**(b) Percent of class:**

See Item 11 of each cover page. The calculation is based on a total of (i) 142,241,572 Class A ordinary shares and 16,990,000 Class B ordinary shares outstanding of the Issuer as of April 10th, 2026 as reported in the Issuer's annual report on Form 20-F filed on the same date.

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

See Item 5 of each cover page.

**(ii) Shared power to vote or to direct the vote:**

See Item 6 of each cover page.

**(iii) Sole power to dispose or to direct the disposition of:**

See Item 7 of each cover page.

**(iv) Shared power to dispose or to direct the disposition of:**

See Item 8 of each cover page.
JIN YIN (BVI) LIMITED is the direct holder of the securities covered by this statement. JIN YIN (BVI) LIMITED is wolly owned by Shanghai Gaopei Duwei Biotechnology Co., Ltd.. Shanghai Gaopei Duwei Biotechnology Co., Ltd. holds 100.0% equity interest of JIN YIN (BVI) LIMITED. Hangzhou Jingyin Investment Partnership (Limited Partnership) holds 99.0% equity interest of Shanghai Gaopei Duwei Biotechnology Co., Ltd. Hangzhou Jingfeng Investment Management Company is the general partner of Hangzhou Jingyin Investment Partnership (Limited Partnership), and may be deemed to beneficially own the ordinary shares beneficially owned by Hangzhou Jingyin Investment Partnership (Limited Partnership). Shijun Feng holds 100.0% equity interest of Hangzhou Jingfeng Investment Management Company. Accoridngly, Shijun Feng may be deemed as the beneficial owner of the ordinary shares of the Issuer held by JIN YIN (BVI) LIMITED.

**Item 5. Ownership of Five Percent or Less of a Class.**

[ ] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**JIN YIN (BVI) LIMITED**

**Date:** 05/14/2026

**By:** /s/ Shijun Feng

**Name & Title:** Shijun Feng/Director

**Shanghai Gaopei Duwei Biotechnology Co., Ltd.**

**Date:** 05/14/2026

**By:** /s/ Shijun Feng

**Name & Title:** Shijun Feng/Director

**Hangzhou Jingyin Investment Partnership (Limited Partnership)**

**Date:** 05/14/2026

**By:** /s/ Yue'ai Jiang

**Name & Title:** Yue'ai Jiang/Authorized Person

**Hangzhou Jingfeng Investment Management Company**

**Date:** 05/14/2026

**By:** /s/ Shijun Feng

**Name & Title:** Shijun Feng/Director

**Shijun Feng**

**Date:** 05/14/2026

**By:** /s/ Shijun Feng

**Name & Title:** Shijun Feng